Dagmar Rosa-Bjorkeson Net Worth

Dagmar Rosa-Bjorkeson biography

Dagmar Rosa-Bjorkeson serves as Independent Director of the Company. Ms. Rosa-Bjorkeson joined our Board of Directors in December 2019. Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development and operational execution. From April 2018 to January 2020, she was executive vice president and chief strategy and development officer at Mallinckrodt Pharmaceuticals, where she was responsible for corporate and therapeutic area strategy, business development and new product commercialization. She joined Mallinckrodt in 2017 as senior vice president of new product commercialization, in which she was responsible for shaping the company’s pipeline programs for optimal patient benefit and access. From 2014 to 2016, Ms. Rosa-Bjorkeson was executive vice president and president of biosimilars at Baxalta Incorporated, a role in which she developed the biosimilars strategy, managed post spin-off efforts from Baxter and oversaw a fully integrated unit including program management, research, clinical development, manufacturing, commercialization and business development. From 1997 to 2014, she held various roles of increasing responsibility at Novartis, including vice president and head of its multiple sclerosis business unit; vice president, business development and licensing, U.S.; vice president, respiratory, U.S.; and country head and president for Novartis Sweden. Ms. Rosa-Bjorkeson’s experience spanned sales, marketing, general management and country operations, and she led multiple launches including the successful launch of Gilenya (fingolimod). Ms. Rosa-Bjorkeson earned an MBA, an M.S. in chemistry and a B.S. in chemistry from the University of Texas, Austin.

What is the salary of Dagmar Bjorkeson?

As the Independent Director of Xencor Inc, the total compensation of Dagmar Bjorkeson at Xencor Inc is 306,505$. There are 11 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of 3,731,510$.

How old is Dagmar Bjorkeson?

Dagmar Bjorkeson is 56, she's been the Independent Director of Xencor Inc since 2019. There are 7 older and 10 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.

What's Dagmar Bjorkeson's mailing address?

Dagmar's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.

Insiders trading at Xencor Inc

Over the last 11 years, insiders at Xencor Inc have traded over 93,804,287$ worth of Xencor Inc stock and bought 1,139,502 units worth 15,515,932$ . The most active insiders traders include Capital, Llcstafford John S...、John S Iii Stafford、John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of 779,296$. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth 536,500$.

What does Xencor Inc do?

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product

Xencor Inc executives and stock owners

Xencor Inc executives and other stock owners filed with the SEC include:

• Bassil Dahiyat,
  President, Chief Executive Officer, Founder and Director
• Allen Yang,
  Senior Vice President, Chief Medical Officer
• Celia Eckert,
  Vice President, General Counsel, Corporate Secretary
• John Desjarlais,
  Senior Vice President, Research and Chief Scientific Officer
• John Kuch,
  Chief Financial Officer, Vice President
• Dr. Bassil I. Dahiyat Ph.D.,
  Co-Founder, CEO, Pres & Director
• Dr. Allen S. Yang M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Dr. John R. Desjarlais,
  Sr. VP of Research & Chief Scientific Officer
• Celia E. Eckert J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• John J. Kuch,
  Sr. VP & CFO
• A. Bruce Montgomery,
  Lead Independent Director
• Dagmar Rosa-Bjorkeson,
  Independent Director
• Kurt Gustafson,
  Independent Director
• Yujiro Hata,
  Independent Director
• Richard Ranieri,
  Independent Director
• Kevin Gorman,
  Independent Director
• Ellen Feigal,
  Independent Director
• Julie Casciani,
  Executive Director - Human Resources
• Kirk Rosemark,
  Vice President, Regulatory Affairs and Quality Assurance
• Eric Kowack,
  Vice President, Program Leadership and Strategic Alliances
• Jeremy Grunstein,
  Vice President of Business Development
• Kirk Rosemark RAC,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Jennifer Sandoz,
  VP of HR
• Charles Liles,
  Associate Director and Head of Corp. Communications & Investor Relations
• John S Iii Ronin Capital, L...,
  
• Paul A Foster,
  Chief Medical Officer
• Barbara Klencke,
  Director
• Bruce L A Carter,
  Director
• Edgardo Jr Baracchini,
  Chief Business Officer
• Robert Jr. Baltera,
  Director
• Bart Jan Cornelissen,
  SR. VICE PRESIDENT & CFO
• John S Jr Stafford,
  10% owner
• Trading, Llc Ronin,
  10% owner
• Lloyd A Rowland,
  Sr. V.P. and General Counsel
• Atul Saran,
  Director
• Harold R Werner,
  Director
• Jonathan Fleming,
  Director
• John S Iii Stafford,
  10% owner
• Capital, Llcstafford John S...,
  
• Nancy Valente,
  EVP, Chief Development Officer